How is androgen-dependent metastatic prostate cancer best treated?

[1]  B. Chabner,et al.  Suramin and prostate cancer: where do we go from here? , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  O. Dalesio,et al.  MAXIMUM ANDROGEN BLOCKADE IN ADVANCED PROSTATE-CANCER - AN OVERVIEW OF 22 RANDOMIZED TRIALS WITH 3283 DEATHS IN 5710 PATIENTS , 1995 .

[3]  H. Rao.  Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients , 1995, The Lancet.

[4]  R. Paridaens,et al.  Interim Results on a Randomized Trial of Mitomycin C in Combination with Orchidectomy for Newly Diagnosed Metastatic Prostate Cancer , 1995, American journal of clinical oncology.

[5]  J. Fowler,et al.  Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer. , 1995, The Journal of urology.

[6]  A. Bergh,et al.  Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. , 1995, The American journal of pathology.

[7]  M. Gleave,et al.  Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. , 1995, Urology.

[8]  E D Crawford,et al.  Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer. , 1995, Urology.

[9]  R. B. Smith,et al.  The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. , 1994, The Journal of urology.

[10]  D. Paulson.  Impact of radical prostatectomy in the management of clinically localized disease. , 1994, The Journal of urology.

[11]  P. Scardino,et al.  Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? , 1994, The Journal of urology.

[12]  S. Hancock,et al.  Control of prostate cancer with radiotherapy: long-term results. , 1994, The Journal of urology.

[13]  G. Murphy,et al.  National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer. , 1994, The Journal of urology.

[14]  J. Oesterling,et al.  Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. , 1994, The Journal of urology.

[15]  W. Catalona,et al.  5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. , 1994, The Journal of urology.

[16]  A. Partin,et al.  Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. , 1994, The Journal of urology.

[17]  W. Shipley,et al.  Early prostate cancer: the national results of radiation treatment from the Patterns of Care and Radiation Therapy Oncology Group studies with prospects for improvement with conformal radiation and adjuvant androgen deprivation. , 1994, The Journal of urology.

[18]  E. Crawford,et al.  Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036. , 1994, Seminars in oncology.

[19]  H I Scher,et al.  Bone metastases: improving the therapeutic index. , 1994, Seminars in oncology.

[20]  K. Griffiths,et al.  Hormonal treatment of advanced disease: some newer aspects. , 1994, Seminars in oncology.

[21]  F. Cope,et al.  Apoptosis II: The Molecular Basis of Apoptosis in Disease , 1994 .

[22]  J. P. Francois,et al.  Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients). , 1994, British journal of urology.

[23]  L. Weissbach,et al.  Primary therapy of metastatic prostate carcinoma with depot gonadotropin-releasing hormone analogue goserelin versus estramustine phosphate. The Prostate Cancer Study Group. , 1994, Urology.

[24]  I. Christensen,et al.  Long‐term results of danish prostatic cancer group trial 86. Goserelin acetate plus flutamide versus orchiectomy in advanced prostate cancer , 1993, Cancer.

[25]  J. Klijn,et al.  Short‐term versus long‐term addition of cyproterone acetate to buserelin therapy in comparison with orchidectomy in the treatment of metastatic prostate cancer , 1993, Cancer.

[26]  P. Ferrari,et al.  Combination treatment in M1 prostate cancer , 1993, Cancer.

[27]  M. R. Robinson.  A further analysis of european organization for research and treatment of cancer protocol 30805. Orchidectomy versus orchidectomy plus cyproterone acetate versus low‐dose diethylstilbestrol , 1993, Cancer.

[28]  R. Sylvester,et al.  Orchidectomy versus goserelin plus flutamide in patients with metastatic prostate cancer (EORTC 30853) , 1993, Cancer.

[29]  Andriole Gl,et al.  Serum PSA after antiandrogen therapy. , 1993 .

[30]  T. Jacks,et al.  Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[31]  W. Catalona,et al.  Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. , 1993, JAMA.

[32]  P. Schellhammer,et al.  Prognostic factors in stage D2 prostate cancer treated with a pure nonsteroidal antiandrogen , 1993, Cancer.

[33]  R. Sylvester,et al.  Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. , 1993, Urology.

[34]  D. Wysowski,et al.  Fatal and Nonfatal Hepatotoxicity Associated with Flutamide , 1993, Annals of Internal Medicine.

[35]  S. Goldenberg,et al.  Effects of intermittent androgen suppression on androgen‐dependent tumors. Apoptosis and serum prostate‐specific antigen , 1993, Cancer.

[36]  J. Geller.  Basis for hormonal management of advanced prostate cancer , 1993, Cancer.

[37]  L. Denis.  Prostate cancer. Primary hormonal treatment , 1993, Cancer.

[38]  M. Soloway,et al.  Antiandrogenic agents as monotherapy in advanced prostatic carcinoma , 1993, Cancer.

[39]  J. Simard,et al.  Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first‐line therapy , 1993, Cancer.

[40]  L. Denis,et al.  Ketoconazole and liarozole in the treatment of advanced prostatic cancer , 1993, Cancer.

[41]  H. Herr,et al.  A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy , 1993, Cancer.

[42]  M. Soloway,et al.  Prognostic significance of changes in prostate‐specific markers after endocrine treatment of stage D2 prostatic cancer , 1992, Cancer.

[43]  P. Pfitzenmeyer,et al.  Nilutamide pneumonitis: a report on eight patients. , 1992, Thorax.

[44]  P. Vihko,et al.  Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line. , 1992, Endocrinology.

[45]  F. Boccardo,et al.  A Multicenter Randomized Trial Comparing the Luteinizing Hormone-Releasing Hormone Analogue Goserelin Acetate Alone and with Flutamide in the Treatment of Advanced Prostate Cancer , 1991 .

[46]  L. Holmberg,et al.  Prognostic factors in progression-free survival and corrected survival in patients with advanced prostatic cancer: results from a randomized study comprising 150 patients treated with orchiectomy or estrogens. , 1991, The Journal of urology.

[47]  J. Goméz,et al.  Prostate specific antigen and prostatic acid phosphatase for monitoring therapy of carcinoma of the prostate. , 1991, The Journal of urology.

[48]  J. Hanson,et al.  Analysis of prognostic factors in men with metastatic prostate cancer. Uro-Oncology Group of Northern Alberta. , 1991, The Journal of urology.

[49]  M. Costantini,et al.  Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project. , 1991, The Journal of urology.

[50]  D. Tindall,et al.  Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. , 1991, Cancer research.

[51]  J. Oesterling,et al.  Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status? , 1991, The Journal of urology.

[52]  N. Vogelzang,et al.  Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. , 1991, JAMA.

[53]  N. Vogelzang,et al.  Independent Prognostic Factors in Patients With Metastatic (Stage D2) Prostate Cancer , 1991 .

[54]  J. Geller.  Megestrol acetate plus low-dose estrogen in the management of advanced prostatic carcinoma. , 1991, The Urologic clinics of North America.

[55]  S. Goldenberg,et al.  Use of cyproterone acetate in prostate cancer. , 1991, The Urologic clinics of North America.

[56]  J. Trachtenberg,et al.  Total androgen ablation: Canadian experience. , 1991, The Urologic clinics of North America.

[57]  F. Lowe,et al.  Indications for use of ketoconazolein management of metastatic prostate cancer , 1990 .

[58]  O. Yoshida,et al.  Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer. , 1990, The Journal of urology.

[59]  I. Thompson,et al.  Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. , 1990, The Journal of urology.

[60]  C. Osborne,et al.  Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  R. Sylvester,et al.  Prostatic Specific Antigen and the Prediction of Prognosis in Metastatic Prostatic Cancer , 1990, Cancer.

[62]  C. Rose,et al.  A Phase III Trial of Zoladex and Flutamide Versus Orchiectomy in the Treatment of Patients With Advanced Carcinoma of the Prostate , 1990, Cancer.

[63]  M. Soloway.  The Importance of Prognostic Factors in Advanced Prostate Cancer , 1990, Cancer.

[64]  F. Debruyne,et al.  Analysis of prognostic factors in disseminated prostatic cancer. An update , 1990 .

[65]  V. Vinciguerra,et al.  Predictive initial parameters for response of stage D prostate cancer to treatment with the luteinizing hormone-releasing hormone agonist goserelin. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  A. Coldman,et al.  Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. , 1990, Cancer research.

[67]  J. Oesterling,et al.  Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. , 1990, The Journal of urology.

[68]  M. Keating,et al.  Long-term experience with flutamide in patients with prostatic carcinoma. , 1989, Urology.

[69]  P. Goodman,et al.  A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. , 1989, The New England journal of medicine.

[70]  J. Fiet,et al.  Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). , 1989, The New England journal of medicine.

[71]  W. Peeling,et al.  Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. , 1989, Urology.

[72]  S. Ishikawa,et al.  Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. , 1989, The Journal of urology.

[73]  P. Schellhammer,et al.  Patients' choice of treatment in stage D prostate cancer. , 1989, Urology.

[74]  R. Sylvester,et al.  Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on Treatment of Cancer trials. , 1989, The Journal of urology.

[75]  Z. Braf,et al.  Changes in prostate‐specific markers under chronic gonadotrophin‐releasing hormone analogue treatment of stage D prostatic cancer , 1989, Cancer.

[76]  D. Byar,et al.  Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. , 1989, NCI monographs : a publication of the National Cancer Institute.

[77]  S. Goldenberg,et al.  The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma. , 1988, The Journal of urology.

[78]  G. Murphy,et al.  A comparison of diethylstilbestrol or orchiectomy with buserelin and with methotrexate plus diethylstilbestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate , 1988, Cancer.

[79]  D. Tolley,et al.  Ketoconazole as primary treatment of prostatic cancer. , 1988, British journal of urology.

[80]  L. Klotz,et al.  Megestrol acetate plus minidose diethylstilbestrol in the treatment of carcinoma of the prostate. , 1988, Seminars in oncology.

[81]  N. Kyprianou,et al.  Activation of programmed cell death in the rat ventral prostate after castration. , 1988, Endocrinology.

[82]  F. Rasmussen,et al.  Flutamide versus stilboestrol in the management of advanced prostatic cancer. A controlled prospective study. , 1988, British journal of urology.

[83]  H. Lepor,et al.  Disseminated intravascular coagulation in prostatic carcinoma reversed by ketoconazole. , 1987, JAMA.

[84]  K. Ang,et al.  Ketoconazole therapy for advanced prostatic cancer: feasibility and treatment results. , 1987, The Journal of urology.

[85]  A. Pont,et al.  Long-term experience with high dose ketoconazole therapy in patients with stage D2 prostatic carcinoma. , 1987, The Journal of urology.

[86]  R. Lundgren.  Flutamide as primary treatment for metastatic prostatic cancer. , 1987, British journal of urology.

[87]  L. Denis,et al.  Biochemical monitoring of carcinoma of prostate treated with an LH-RH analogue (Zoladex). , 1986, British journal of urology.

[88]  M. Soloway,et al.  Pre-treatment testosterone levels: significance in androgen deprivation therapy. , 1986, The Journal of urology.

[89]  R. Makuch,et al.  A trial of combination chemotherapy followed by hormonal therapy for previously untreated metastatic carcinoma of the prostate. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  R. Sylvester,et al.  Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. , 1986, The Journal of urology.

[91]  R. Sylvester,et al.  A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the European Organization for Research on Treatment of Cancer. , 1986, The Journal of urology.

[92]  A. Bélanger,et al.  Levels of plasma steroid glucuronides in intact and castrated men with prostatic cancer. , 1986, The Journal of clinical endocrinology and metabolism.

[93]  S. Lightman,et al.  RANDOMISED CONTROLLED STUDY OF ORCHIDECTOMY VS LONG-ACTING D-TRP-6-LHRH MICROCAPSULES IN ADVANCED PROSTATIC CARCINOMA , 1985, The Lancet.

[94]  R. Priore,et al.  Prognostic factors in patients with advanced stage prostate cancer. , 1985, Cancer research.

[95]  R. Sharifi,et al.  Comparison of leuprolide and diethylstilbestrol for stage D2 adenocarcinoma of prostate. , 1985, Urology.

[96]  I. Tannock.  Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  R. Wittes,et al.  A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  D. Tolley,et al.  Flutamide therapy for advanced prostatic cancer: a phase II study. , 1985, British journal of urology.

[99]  J. Wolter,et al.  Megestrol acetate used as primary hormonal therapy in stage D prostatic cancer. , 1985, Seminars in oncology.

[100]  M. Hida,et al.  Metastatic patterns of prostatic cancer: Correlation between sites and number of organs involved , 1984, Cancer.

[101]  J. Geller,et al.  Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy. , 1984, The Journal of urology.

[102]  J. Trachtenberg,et al.  KETOCONAZOLE THERAPY FOR ADVANCED PROSTATE CANCER , 1984, The Lancet.

[103]  S. Fosså,et al.  Carcinoma of the prostate with soft tissue or non-regional lymphatic metastases at the time of diagnosis: a review of 47 cases. , 1984, British journal of urology.

[104]  I. Kemp,et al.  Cancer of the prostate. Do younger men have a poorer survival rate? , 1984, British journal of urology.

[105]  P. Brawn.  The dedifferentiation of prostate carcinoma , 1983, Cancer.

[106]  J. Trachtenberg,et al.  Ketoconazole: a novel and rapid treatment for advanced prostatic cancer. , 1983, The Journal of urology.

[107]  S. Jacobs.  Spread of prostatic cancer to bone. , 1983, Urology.

[108]  P. Scardino,et al.  Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone , 1983, Cancer.

[109]  D. Stevens,et al.  Ketoconazole blocks testosterone synthesis. , 1982, Archives of internal medicine.

[110]  W. Vale,et al.  Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men: an approach toward the development of a male contraceptive. , 1981, The New England journal of medicine.

[111]  S. Yen,et al.  Medical castration of males with megestrol acetate and small doses of diethylstilbestrol. , 1981, The Journal of clinical endocrinology and metabolism.

[112]  W. Whitmore,et al.  Experience with flutamide in previously untreated patients with advanced prostatic cancer. , 1979, The Journal of urology.

[113]  S. Yen,et al.  Treatment of advanced cancer of prostate with megestrol acetate. , 1978, Urology.

[114]  J. Schmidt,et al.  Comparison of flutamide (SCH-13521) and diethylstilbestrol in untreated advanced prostatic cancer. , 1976, Urology.

[115]  D. Byar,et al.  Carcinoma of prostate. Correlation between radiologic quantitation of metastases and patient survival. , 1975, Urology.

[116]  Day Pr.  Letter: Care of children's eyes. , 1973, Lancet.

[117]  A. Schally,et al.  Isolation and properties of the FSH and LH-releasing hormone. , 1971, Biochemical and biophysical research communications.

[118]  D. Byar,et al.  Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate , 1970, Cancer.

[119]  D. Byar,et al.  Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo , 1970, Cancer.

[120]  J. Bailar,et al.  Factors in the prognosis of carcinoma of the prostate: a cooperative study. The Veterans Administration Cooperative Urological Research Group. , 1968, The Journal of urology.

[121]  A. deMoura,et al.  [Cancer of the prostate]. , 1962, Jornal do medico.

[122]  M. Elkin,et al.  Metastases from cancer of the prostate. Autopsy and roentgenological findings , 1954, Cancer.

[123]  F. K. Arnheim.  Carcinoma of the Prostate: A Study of the Postmortem Findings in One Hundred and Seventy-Six Cases , 1948 .

[124]  C. Huggins,et al.  STUDIES ON PROSTATIC CANCER: II. THE EFFECTS OF CASTRATION ON ADVANCED CARCINOMA OF THE PROSTATE GLAND , 1941 .

[125]  C. Huggins,et al.  Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. , 1941, CA: a cancer journal for clinicians.

[126]  E. Mintz,et al.  Autopsy Findings in 100 Cases of Prostatic Cancer , 1934 .

[127]  A. T. Cabot.  II. The Question of Castration for Enlarged Prostate. , 1896, Annals of surgery.

[128]  J. W. White.  II. The Present Position of the Surgery of the Hypertrophied Prostate. , 1893, Annals of surgery.

[129]  P. Schellhammer,et al.  Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group. , 1996, Urology.

[130]  P. Wingo,et al.  Cancer statistics, 1996 , 1996, CA: a cancer journal for clinicians.

[131]  P. Iversen.  Update of monotherapy trials with the new anti-androgen, Casodex (ICI 176,334). International Casodex Investigators. , 1994, European urology.

[132]  M. Ziveri,et al.  Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group. , 1993, European journal of cancer.

[133]  E. Crawford,et al.  Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. , 1993, The Journal of urology.

[134]  P. Schellhammer,et al.  Zoladex versus orchiectomy in treatmentof advanced prostate cancer: a randomized trial , 1991 .

[135]  W. Catalona.  Patient selection for, results of, and impact on tumor resection of potency-sparing radical prostatectomy. , 1990, The Urologic clinics of North America.

[136]  M. Soloway,et al.  Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan , 1988, Cancer.

[137]  N. Kyprianou,et al.  Activation of a Ca2+−Mg2+‐dependent endonuclease as an early event in castration‐induced prostatic cell death , 1988, The Prostate.

[138]  R. Babaian,et al.  Medical castration using megestrol acetate and minidose estrogen. , 1988, Urology.

[139]  F. Labrie,et al.  LHRH Agonists and Antiandrogens in Prostate Cancer , 1987 .

[140]  K. Griffiths,et al.  Treatment of patients with advanced cancer of the prostate: phase III trial, zoladex against castration; a study of the British Prostate Group. , 1987, Journal of steroid biochemistry.

[141]  W. Whitmore,et al.  Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy , 1984, Cancer.

[142]  J. BotellaLlusiá,et al.  [Long-term results]. , 1983, Anales de la Real Academia Nacional de Medicina.

[143]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[144]  Byar Dp.  VACURG studies of conservative treatment. , 1980 .

[145]  Blackard Ce.  The Veterans' Administration Cooperative Urological Research Group studies of carcinoma of the prostate: a review. , 1975 .

[146]  K. Griffiths,et al.  Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro. , 1974, The Journal of endocrinology.